{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:41:07Z","timestamp":1785192067982,"version":"3.55.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"11","funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2015,11,2]]},"DOI":"10.1021\/acs.molpharmaceut.5b00278","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T20:23:24Z","timestamp":1443731004000},"page":"4166-4173","source":"Crossref","is-referenced-by-count":31,"title":["Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide"],"prefix":"10.1021","volume":"12","author":[{"given":"Monika","family":"Malm-Erjef\u00e4lt","sequence":"first","affiliation":[{"name":"Novo Nordisk A\/S, 2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Ekblom","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, 2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vouis","sequence":"additional","affiliation":[{"name":"Phase\rI Services, Quintiles AB, SE-753 23 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Zdravkovic","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, 2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[{"name":"Biopharmaceutics,\rDepartment of Pharmacy, Uppsala University, SE-751 23 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S37644"},{"key":"ref2\/cit2","unstructured":"Food and Drug Administration (FDA). Victoza prescribinginformation. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf. Accessed date April 9 2015."},{"key":"ref3\/cit3","unstructured":"European Medicines Agency (EMA). Summary of product characteristics\u2013 Victoza. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001026\/WC500050017.pdf. Accessed date April 9 2015."},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1080\/00365520701370922"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0110-x"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01557.x"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.109"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016212804288"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-004-9004-4"},{"key":"ref10\/cit10","unstructured":"Griseofulvin drug information. Available at:http:\/\/www.mims.com\/USA\/drug\/info\/Griseofulvin%20Suspension\/?type=full. Accessed date April 9 2015."},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1007\/BF01540341"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1260169"},{"key":"ref13\/cit13","unstructured":"Atorvastatin SPC. Available at:http:\/\/www.medicines.org.uk\/emc\/medicine\/1424\/SPC\/. Accessed April 9 2015."},{"key":"ref14\/cit14","unstructured":"Lisinopril SPC. Available at:https:\/\/www.medicines.org.uk\/emc\/medicine\/23998. Accessed date April 9 2015."},{"key":"ref15\/cit15","unstructured":"Digoxin SPC. Available at:https:\/\/www.medicines.org.uk\/emc\/medicine\/23944. Accessed date April 9 2015."},{"key":"ref16\/cit16","unstructured":"Declaration of Helsinki. Available at:http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/17c.pdf. Accessed date April 9 2015."},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-001-0719-z"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009339189"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389468"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2008.07.002"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.02.010"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0044-y"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389471"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-12-8"},{"key":"ref25\/cit25","unstructured":"Food and Drug Administration (FDA). Byetta SPC. https:\/\/www.medicines.org.uk\/emc\/medicine\/19257. Accessed date April 9 2015."},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006291622"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.5414\/CPP45114"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47651"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005278806"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106457"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2006.01.001"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1609"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5b00278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T03:49:43Z","timestamp":1681616983000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.5b00278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11,2]]}},"alternative-id":["10.1021\/acs.molpharmaceut.5b00278"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00278","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}